Nurix Therapeutics Announces Presentations at Discovery on Target Conference
Nurix Therapeutics (Nasdaq: NRIX) announced three oral presentations at the 22nd Annual Discovery on Target conference in Boston, MA, from September 30 to October 3, 2024. The presentations highlight Nurix's DELigase platform capabilities in addressing difficult-to-drug target classes like E3 ligases and transcription factors. The company will present on:
1. A small molecule inhibitor of CBL-B for enhanced T-cell function
2. The chemical space of bi-functional degraders targeting the CNS, including their clinical stage BTK degrader NX-5948
3. Screening DNA binding proteins with DNA Encoded Libraries, focusing on transcription factors
The presentation slides will be available on Nurix's website from October 1, 2024.
Nurix Therapeutics (Nasdaq: NRIX) ha annunciato tre presentazioni orali alla 22ª Conferenza Annuale Discovery on Target a Boston, MA, dal 30 settembre al 3 ottobre 2024. Le presentazioni mettono in evidenza le capacità della piattaforma DELigase di Nurix nell'affrontare classi di obiettivi difficili da trattare come le ligasi E3 e i fattori di trascrizione. L'azienda presenterà su:
1. Un inibitore a piccole molecole di CBL-B per migliorare la funzione delle cellule T
2. Lo spazio chimico degli degradatori bifunzionali mirati al SNC, incluso il loro degradatore BTK in fase clinica NX-5948
3. Screening di proteine leganti il DNA con Biblioteche Codificate a DNA, concentrandosi sui fattori di trascrizione
Le diapositive delle presentazioni saranno disponibili sul sito web di Nurix a partire dal 1 ottobre 2024.
Nurix Therapeutics (Nasdaq: NRIX) anunció tres presentaciones orales en la 22ª Conferencia Anual Discovery on Target en Boston, MA, del 30 de septiembre al 3 de octubre de 2024. Las presentaciones destacan las capacidades de la plataforma DELigase de Nurix para abordar clases de objetivos difíciles de tratar, como las ligasas E3 y los factores de transcripción. La compañía presentará sobre:
1. Un inhibidor de pequeñas moléculas de CBL-B para mejorar la función de las células T
2. El espacio químico de los degradadores bifuncionales dirigidos al SNC, incluyendo su degradador BTK en etapa clínica NX-5948
3. Tamizaje de proteínas que se unen al ADN con Bibliotecas Codificadas de ADN, centrándose en factores de transcripción
Las diapositivas de la presentación estarán disponibles en el sitio web de Nurix a partir del 1 de octubre de 2024.
Nurix Therapeutics (Nasdaq: NRIX)는 2024년 9월 30일부터 10월 3일까지 매사추세츠주 보스턴에서 열리는 제22회 Discovery on Target 컨퍼런스에서 세 개의 구두 발표를 발표했습니다. 발표에서는 E3 리가제 및 전사 인자와 같은 치료하기 어려운 타겟 클래스를 다루는 Nurix의 DELigase 플랫폼의 기능이 강조됩니다. 회사는 다음과 같은 주제로 발표할 예정입니다:
1. T세포 기능 강화를 위한 CBL-B의 작은 분자 억제제
2. CNS를 타겟으로 하는 이중 기능성 분해 효소의 화학적 공간, 그들의 임상 단계 BTK 분해 효소 NX-5948 포함
3. 전사 인자에 중점을 둔 DNA 인코딩 라이브러리를 이용한 DNA 결합 단백질 스크리닝
발표 슬라이드는 2024년 10월 1일부터 Nurix 웹사이트에서 확인할 수 있습니다.
Nurix Therapeutics (Nasdaq: NRIX) a annoncé trois présentations orales lors de la 22ème Conférence Annuelle Discovery on Target à Boston, MA, du 30 septembre au 3 octobre 2024. Les présentations soulignent les capacités de la plateforme DELigase de Nurix pour aborder des classes de cibles difficiles à traiter, comme les ligases E3 et les facteurs de transcription. La société présentera sur :
1. Un inhibiteur de petites molécules de CBL-B pour améliorer la fonction des cellules T
2. L'espace chimique des dégradants bifonctionnels ciblant le SNC, y compris leur dégradant BTK en phase clinique NX-5948
3. Le criblage de protéines liant l'ADN avec des Bibliothèques Codées par l'ADN, en se concentrant sur les facteurs de transcription
Les diapositives de la présentation seront disponibles sur le site Web de Nurix à partir du 1er octobre 2024.
Nurix Therapeutics (Nasdaq: NRIX) hat drei mündliche Präsentationen auf der 22. jährlichen Discovery on Target-Konferenz in Boston, MA, vom 30. September bis 3. Oktober 2024 angekündigt. Die Präsentationen heben die Fähigkeiten der DELigase-Plattform von Nurix hervor, um schwierig zu behandelnde Zielklassen wie E3-Ligasen und Transkriptionsfaktoren anzugehen. Das Unternehmen wird zu folgenden Themen präsentieren:
1. Ein kleines Molekül-Inhibitor von CBL-B zur Verbesserung der T-Zell-Funktion
2. Der chemische Raum von bifunktionalen Abbau-Medikamenten, die auf das ZNS abzielen, einschließlich ihres klinischen BTK-Abbau-Medikaments NX-5948
3. Screening von DNA-bindenden Proteinen mit DNA-enkodierten Bibliotheken, mit Fokus auf Transkriptionsfaktoren
Die Präsentationsfolien werden ab dem 1. Oktober 2024 auf der Website von Nurix verfügbar sein.
- Nurix is presenting three oral presentations at a major industry conference, showcasing their technological capabilities
- The company's DELigase platform can address difficult-to-drug target classes
- Nurix has a clinical stage BTK degrader (NX-5948) showing CNS exposure and activity
- The company has developed a new approach for applying affinity selection to transcription factors
- None.
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced three oral presentations at the 22nd Annual Discovery on Target conference, being held September 30 – October 3, 2024, in Boston, MA.
“The presentations at Discovery on Target highlight Nurix’s ability to repeatedly address difficult-to-drug target classes including E3 ligases and transcription factors using our DELigase platform,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “In addition, we are continuing to expand our knowledge of the properties that govern degrader brain penetration, as exemplified by our NX-5948 program.”
Poster Presentation Details:
Title: Rational Discovery of a Small Molecule Intramolecular Glue Inhibitor of CBL-B that Enhances T-cell Function
Presenting author: Stefan Gajewski, Ph.D.
Date and time: Tuesday, October 1, 10:05 AM ET
Description: Casitas B lymphoma-b (CBL-B) is a RING-type E3 ubiquitin ligase that plays an important role in regulating T cell function. Loss of CBL-B is associated with enhanced T and NK cell activity which makes it an interesting target for immuno-oncology drug development. We present a rational approach to discover and optimize small molecule inhibitors for CBL-B that elicit a potent T cell activation and antitumor activity.
Title: The Evolving Chemical Space of Bi-functional Degraders Targeting the CNS
Presenting author: Wylie S. Palmer, Ph.D.
Date and time: Tuesday, October 1, 5:05 PM ET
Description: Bi-functional degraders occupy beyond-rule-of-five chemical space where established rules for drug-likeness cannot easily be applied. In contrast to approved CNS drugs, bi-functional degraders violate most metrics, particularly molecular weight, yet we routinely observe brain penetrance in our programs. For example, NX-5948, a clinical stage orally bioavailable BTK degrader shows CNS exposure and activity both preclinically and clinically. This presentation will explore our evolving understanding of targeting the CNS using degraders.
Title: Screening DNA Binding Proteins with DNA Encoded Libraries
Presenting author: Christopher B. Phelps, Ph.D.
Date and time: Thursday, October 3, 11:45 AM ET
Description: Transcription factors are historically a challenging target class to drug. Although DNA-encoded libraries (DEL) have become a staple for ligand discovery, transcription factors and other proteins that specifically bind DNA present distinct challenges for DEL technology. Nurix has developed a broadly applicable approach for applying affinity selection and informatic methods to transcription factors, and these methods have yielded tractable hits for the EWS-FLI1 fusion oncoprotein.
The slides for these presentations may be accessed beginning on October 1, 2024, via links in the Scientific Resources section of the Nurix website.
About NX-5948
NX-5948 is an investigational, orally bioavailable degrader of BTK that is currently being evaluated in a Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies. Additional information on the Phase 1a/b clinical trial can be accessed at www.clinicaltrials.gov (NCT05131022).
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended May 31, 2024, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What is Nurix Therapeutics presenting at the Discovery on Target conference in 2024?
What is the significance of Nurix's NX-5948 degrader mentioned in the press release?
How is Nurix Therapeutics (NRIX) addressing the challenge of drugging transcription factors?
When will the presentation slides from Nurix Therapeutics' (NRIX) Discovery on Target conference be available?
